This week on Contemporary OB/GYN®: Jan. 3 to Jan. 7


A look at what's coming to Contemporary OB/GYN® this week

FDA authorizes Pfizer, Merck COVID-19 antiviral pills

The moves bring two new weapons to the toolbox for physicians fighting the pandemic.

Read more

Top 3 challenges of 2022

Each year, the Medical Economics® team surveys their audience to find out what big challenges practitioners faced. By far, the top answer was “administrative burdens,” including staffing, prior authorizations and electronic health records (EHRs). Let's take a closer look at what these burdens entail to help physicians get ready for whatever challenges 2022 will bring.

Read more

Hair dyes, bleach, relaxers, and mousse associated with lower levels of sex steroid hormones

A new Rutgers study indicates a connection between specific personal care products and lower levels of sex steroid hormones, which have a critical role in maintaining pregnancy and fetal development.

Coming soon

Pap Talk: Season 4

With the new year, Contemporary OB/GYN® kicks off a new season of its Pap Talk podcast on Wednesday, Jan. 5.

Coming soon

Community births, and risks, increase with COVID-19 pandemic

New research in the American Journal of Obstetrics and Gynecology showed a rise in community births during the COVID-19 pandemic, as many women thought a hospital delivery to be more dangerous. The data told a different story.

Coming soon

Related Videos
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Navigating vasomotor symptoms in breast cancer patients | Image Credit:
Fertility counseling for oncology patients | Image Credit:
Learning what women prefer in STI preventive care
Related Content
© 2024 MJH Life Sciences

All rights reserved.